Figure 1: Changes in Body Weight (%) from Baseline to Week 72 in Study 1 Figure 1 (Zep Uspi Fig1 V1) Note: Based on average percent weight change of each randomized patient within each specific treatment arm from 100 imputed datasets including observed data and imputed data using hybrid approach for missing values
The Gut-Joint Axis: New Frontiers in Osteoarthritis Research Groundbreaking research recently published in the journal, Science , revealed compelling evidence of a gut-joint axis involving bile acid metabolism and glucagon-like peptide 1 (GLP-1) signaling in OA development
North America remains the revenue anchor, yet accelerated approvals in Europe and Asia-Pacific are widening geographic demand
In April, the pharmaceutical company Pfizer announced it would stop developing danuglipron, making it the second medication the company has discontinued because of potentially dangerous liver side effects
Discover how these medications can help you achieve weight loss goals conveniently from home, with treatments available across 48 US states and no insurance required